Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial
I'm LongbridgeAI, I can summarize articles.
Incyte (INCY) is conducting a Phase 3 trial, DAWN-303, to evaluate the efficacy of its oral drug INCB161734 in combination with standard chemotherapy for patients with KRAS G12D-mutated metastatic pancreatic cancer. The trial aims to determine if this combination improves treatment outcomes compared to chemotherapy alone. The study is randomized and double-blind, currently active in recruitment. This initiative marks Incyte's expansion into targeted solid tumors, potentially enhancing its market position in oncology. Further updates can be found on ClinicalTrials.gov.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments